## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPRO	OVAL
OMB Number:	3235-0287
Estimated average b	ourden
hours per response	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

### STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Responses)														
1. Name and Address of Reporting Person* Tsuchimoto Kim R				2. Issuer Name and Ticker or Trading Symbol Monopar Therapeutics [MNPR]						5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle) 1000 SKOKIE BLVD SUITE 350				3. Date of Earliest Transaction (Month/Day/Year) 06/30/2021						X Officer (give title below) Other (specify below)  Chief Financial Officer				ow)
(Street) WILMETTE, IL 60091				4. If Amendment, Date Original Filed(Month/Day/Year)						6. Individual or Joint/Group Filing(Check Applicable Line)  Form filed by One Reporting Person  Form filed by More than One Reporting Person				
	(State)	(Zip)			Table I -	Non-De	rivativ	e Securiti	es Acquire	d, Dispose	d of, or Ben	eficially Owr	ed	
1.Title of Security (Instr. 3)		2. Transaction Date (Month/Day/Year)	any	f Code (Instr. 8	(Instr. 8)		4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		Owned Following Reported Transaction(s)		ted [	Ownership Form:	Beneficial	
					. v	Amou			isu. 3 and 4	3 and 4)			Ownership (Instr. 4)	
tock	(	06/30/2021			M		2,442	2 A	<u>(1)</u> 3,	3,494		]	)	
tock		06/30/2021			F		823	D	\$ 5.89 2,	2,671			)	
										wned				
2. Conversion or Exercise Price of		3A. Deemed Execution Date, any	if Code 4.	ealls, v	Number f derivative ecurities	ired, Disoptions, 6. Date and Ex	ained i displa sposed conver e Exerci spiration	of, or Bertible securisable  n Date	rm are not rently valideficially Ourities)  7. Title and of Underly Securities	t required d OMB co wned d Amount ving	to resport ontrol numbers of the second seco	9. Number o Derivative Securities Beneficially	f 10. Ownersl Form of Derivati	ve Ownershi
Security Security				(A) Dis of (							Following Reported	Direct (I or Indirect)	D) ect	
			Code	V (	A) (D)	Date Exerci			Title	Amount or Number of Shares				
							2)	<u>(2)</u>	Commor	n 2,442	\$ 0			
	Existence of Derivative	(Street)  SE, IL 60091  (State)  Tock  Toch  Toc	Conversion or Exercise Price of Derivative  Discrete (First) (Middle)  (First) (Middle)  (Street) (Zip)  (Zip)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)  3. Transaction Date (Month/Day/Year)  (Month/Day/Year)	A SKIM R  (First) (SITE BLVD SUITE 350  (Street)  (State)  (State)  (Zip)  (State)  (Zip)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (A If Amend Execution Date (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (A If Amend Execution Date (Month/Day/Year)  (Month/Day/Year)	Monopar Thera  (First) (Middle) 3. Date of Earliest 06/30/2021  (Street) 4. If Amendment,  (State) (Zip) 2A. Deemed Execution Date (Month/Day/Year)  (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) 2A. Deemed Execution Date, i any (Month/Day/Year)  (Month/Day/Year) 2A. Deemed Execution Date, i any (Month/Day/Year)  (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)  (A. 5 Transaction Date (Month/Day/Year) (Month/Day/Year)  (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year) 4A. 5A. Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year) 4A. 5A. Deemed Execution Date, if any (Month/Day/Year)  (Month/Day/Year) 4A. 5A. Deemed Execution Date, if any (Month/Day/Year)	Monopar Therapeutics (First) (Street)  (Street)  (Street)  (Street)  (State)  (Zip)  (Zip)  (State)  (Zip)  (Month/Day/Year)  (Month/Day/Year)  (Month/Day/Year)  (Code (Instr. 8)  Table II - Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)  (Month/Day/Year)  (Month/Day/Year)  (Middle)  3. Date of Earliest Transaction (O6/30/2021)  4. If Amendment, Date Orige  4. If Amendment, Date Orige  (A) or Date (Instr. 8)  (Month/Day/Year)  (Month/Day/Year)  (Middle)  3. Date of Earliest Transaction (Code (Instr. 8))  4. If Amendment, Date Orige  (Instr. 8)  (Instr. 8)  (Month/Day/Year)  (Month/Day/Year)  (Middle)  3. Transaction Date, if Code (Instr. 8)  (Instr. 8)  (Instr. 8)  (Instr. 8)  (Instr. 8)	Monopar Therapeutics   MNP	Monopar Therapeutics [MNPR]  3. Date of Earliest Transaction (Month/Day, 06/30/2021  4. If Amendment, Date Original Filed(Month/Day, 06/30/2021  Table I - Non-Derivativ  2. Transaction Date (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  (Month/Day/Year)  2. Transaction Date (Month/Day/Year)  tock  06/30/2021  M 2,442  Code V Amout (Instr. 8)  Persons with contained if form displated to conversion of conversion Date (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed (e.g., puts, calls, warrants, options, conversion of Code (Month/Day/Year)  Table II - Derivative Securities Acquired, Disposed (A) or Disposed of (D) (Instr. 3, 4, and 5)  Date Exercisable II  Date Exercisable II  Date Exercisable II	Monopar Therapeutics [MNPR]	Monopar Therapeutics [MNPR]   Monopar	Monopar Therapeutics   MNPR	Check   Of-30/2021   State   Code   Code	Check all application   Chec	Okara   Check all applicable   Director   10% Owner   10% Owner

	Relationships					
Reporting Owner Name / Address	Director	10% Owner	Officer	Other		
Tsuchimoto Kim R 1000 SKOKIE BLVD SUITE 350 WILMETTE, IL 60091			Chief Financial Officer			

## **Signatures**

/s/ Kim R. Tsuchimoto	07/02/2021
Signature of Reporting Person	Date

# **Explanation of Responses:**

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Represents shares acquired on vesting and settlement of restricted stock units.
- On January 26, 2021, the reporting person was granted 19,536 restricted stock units, vesting 6/48ths (2,442 shares) on June 30, 2021, and 3/48ths (1,221 shares) every 3 months (2) thereafter until the RSU is fully vested on December 31, 2024. Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. Disposed of restricted stock units were surrendered in exchange for issuance of common stock upon vesting and settlement.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.